Latest news for TOHO (OTC:THOOF) Stock

TOHO Co Ltd is engaged in the purchase, procurement, and development of food for commercial use. The group is also engaged in the production of coffee for commercial use. provides total support for the restaurant business, including logistics, information, and services, to support customer value creation.

TOHO Co Ltd

Palantir Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares have been on a tear, thanks to the excitement ahead of the <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40960886/palantir-dell-to-join-s-p-500-friday-heres-how-tesla-stock-has-performed-since-its-add">company&#8217;s S&amp;P 500 inclusion </a>and the broader market strength. An analyst at Wedbush thinks the stock has further room to run.
The Palantir Analyst: In a note published late Wednesday, analyst Daniel Ives maintained an Outperform rating and lifted the price target for the stock from $38 to $45. The analyst said the upward adjustment accounted for the firm&#8217;s increasing confidence in the enterprise-driven AIP Strategy.
The Palantir Thesis: Wedbush&#8217;s checks indicated that more enterprises are strategically discussing the potential deployment of Palantir&#8217;s proprietary artificial intelligence platform &#8211; the AIP, in 2025, said Ives. &#8220;With AI spending expected to ramp significantly within IT budgets in 2025, we believe the Messi of AI &#8211; Palantir is in a prime spot to continue expanding its pipeline/deal flow,&#8221; the analyst said.
Palantir, according to the analyst, has been expanding use cases for its marquee products that have helped expand its partner ecosystem, with rapidly rising demand across the landscape for enterprise-scale and enterprise-ready generative AI. He sees this as a major growth driver for the U.S. commercial business over the next 12 to 18 months. 
See Also: <a href="https://www.benzinga.com/money/best-artificial-intelligence-stocks">Best AI Stocks</a>
New and existing customers across the commercial and federal government <a href="https://www.benzinga.com/markets/equities/24/09/41023892/palantir-and-apa-amp-up-ai-alliance-multi-million-dollar-deal-to-transform-oil-gas-operations">continue to sign up for Palantir&#8217;s tech stack, </a>Ives said, citing his channel checks. The key for the Alex Karp-led company is boot camp deal conversions, he said, adding that the boot camp strategy has helped the company to fast-track multi-year, multi-million-dollar contracts
From the customer&#8217;s point of view, the analyst said Palantir&#8217;s Foundry and AIP serve as strategic differentiators for enterprises in improving operations at scale. These help address the large concerns of enterprises, he added.
&#8220;In a nutshell, PLTR is firing on all cylinders around AIP and we believe this is a paradigm (and valuation) changer for the Messi of AI heading into 2025,&#8221; Ives said.
Palantir Stock: Palantir ended Wednesday&#8217;s session up 0.60% at $37.12, according to <a href="https://benzinga.grsm.io/register174">Benzinga Pro data.</a> The stock has gained over 116% so far this year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40892076/palantir-key-enabler-of-clients-businesses-says-bullish-analyst-as-ceo-alex-karp-to">Palantir &#8216;Key Enabler&#8217; Of Clients&#8217; Businesses, Says Bullish Analyst, As CEO Alex Karp Touts 10-Fold Growth From Current Levels</a></li>
</ul>
Photo by Iljanaresvara Studio on Shutterstock

Analyst Color

Equities

News

Price Target

Reiteration

Analyst Ratings

Tech

PLTR

Palantir Bull Says AI Platform Will Be Valuation Changer Heading Into 2025, Calls For Incremental 20% Upside For Stock

TD SYNNEX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) will release earnings results for its third quarter, before the <a href="https://www.benzinga.com/quote/SNX/earnings">opening bell on Thursday, Sept. 26.</a>
Analysts expect the Fremont, California-based company to report quarterly earnings at $2.80 per share, up from $2.78 per share in the year-ago period. TD SYNNEX projects to report revenue of $14.11 billion for the quarter, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Sept. 12, TD SYNNEX announced an agreement to acquire IPsense Cloud Migration business in Brazil to create a new cloud competence center for its resellers.
TD SYNNEX shares fell 1.3% to close at $117.29 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TJX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59e5ec72efacff0001d73ba9/vincent-colicchio">Barrington Research analyst Vincent Colicchio</a> maintained an Outperform rating with a price target of $138 on Sept. 23. This analyst has an accuracy rate of 63%.</li>
<li>RBC Capital analyst Ashish Sabadra upgraded the stock from Sector Perform to Outperform rating and boosted the price target from $135 to $140 on July 15. This analyst has an accuracy rate of 74%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/60644e9560c58c0001cd5c0a/david-vogt">UBS analyst David Vogt</a> maintained a Buy rating and raised the price target from $145 to $150 on June 26. This analyst has an accuracy rate of 74%.</li>
<li>JP Morgan analyst Joseph Cardoso maintained a Neutral rating and cut the price target from $126 to $123 on June 26. This analyst has an accuracy rate of 64%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586e4055351b9b00018beea7/tim-long">Barclays analyst Tim Long</a> maintained an Equal-Weight rating and raised the price target from $111 to $118 on March 27. This analyst has an accuracy rate of 74%.</li>
</ul>
Considering buying SNX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/26025814/image-205-1024x517.png" alt="" class="wp-image-566984" style="width:618px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/26025814/image-205-1024x517.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/26025814/image-205-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/26025814/image-205-768x388.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/26025814/image-205.png 1321w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41024505/top-5-industrials-stocks-that-may-collapse-in-q3">Top 5 Industrials Stocks That May Collapse In Q3</a></li>
</ul>

Earnings

Markets

Trading Ideas

TD SYNNEX Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

In a fascinating twist that seems to blur the <a href="https://www.benzinga.com/news/24/09/41038801/spac-king-chamath-palihapitiya-forecasts-how-ai-will-transform-healthcare-sector-its-not-all-roses-b">line between science fiction and reality</a>, tech entrepreneur Chamath Palihapitiya recently shared his vision of artificial intelligence-powered law enforcement on the Joe Rogan Experience podcast. His ideas eerily echo the premise of the 1987 cult classic film &#8220;RoboCop,&#8221; but with a distinctly 21st-century spin.
What Happened: Palihapitiya, a former Facebook executive and current CEO of Social Capital, is no stranger to bold predictions about technology&#8217;s impact on society. 
Known for his shrewd investments in companies like Slack and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), he&#8217;s become a prominent voice in Silicon Valley&#8217;s futurist circles. On Rogan&#8217;s podcast, he painted a picture of law enforcement that could have been ripped from the pages of a sci-fi novel.
&#8220;Imagine if you had a bunch of Optimus, like Tesla&#8217;s robot, and they were the beat cops. They were the highway patrol,&#8221; Palihapitiya proposed. 
This reference to Optimus, Tesla Inc.&#8216;s humanoid robot project, isn&#8217;t coincidental. Tesla&#8217;s CEO, Elon Musk, has been a frequent guest on Rogan&#8217;s podcast, their conversations often venturing into territory that seems more science fiction than science fact.
Musk unveiled the <a href="https://www.benzinga.com/news/24/07/39880470/elon-musk-pushes-back-optimus-timeline-says-teslas-humanoid-robot-will-hopefully-be-available-for-ot">Optimus prototype in 2022</a>, touting it as a general-purpose humanoid robot capable of performing a wide range of tasks. While its current capabilities are limited, Musk&#8217;s vision for Optimus is ambitious, potentially revolutionizing labor across various industries. Palihapitiya&#8217;s suggestion takes this concept a step further, envisioning these robots in law enforcement roles.
&#8220;Now those robots would be controlled remotely, right? So the people that are remote now can be a very different archetype,&#8221; Palihapitiya explained. 
Why It Matters: This concept diverges from &#8220;RoboCop&#8217;s&#8221; cyborg officer, instead proposing fully robotic bodies controlled by human operators. &#8220;Instead of the physical requirements of policing, you now add this other layer, which is the psychological elements and the judgment,&#8221; he added.
The idea isn&#8217;t without merit. In an era where police reform is a hot-button issue, the concept of removing human officers from potentially dangerous situations could <a href="https://www.benzinga.com/news/23/09/34502816/247-security-zero-human-bias-the-era-of-robot-security-guards-is-in-full-swing">reduce risks of escalation and harm</a>. 
&#8220;Well first you don&#8217;t put humans in the way, I suspect then the reaction of those robots could be markedly different,&#8221; Palihapitiya noted.
However, unlike the RoboCop of Paul Verhoeven&#8216;s dystopian Detroit, Palihapitiya acknowledges the limitations of AI in complex decision-making. &#8220;It&#8217;ll take a long time for computers to be able to replace us to do that,&#8221; he said, referring to the nuanced judgments often required in law enforcement situations.
Rogan&#8217;s <a href="https://www.benzinga.com/news/24/05/38978082/joe-rogan-says-elon-musk-is-his-favorite-billionaire-i-will-buy-teslas-as-long-as-they-sell-them-jus">relationship with Musk</a>, marked by controversial podcast episodes featuring open discussions on AI, space exploration, and futurism, has often brought cutting-edge tech concepts to mainstream attention.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41016829/possible-but-not-probable-steve-jobs-witty-transportation-answer-in-1973-resume-earns-him-online-acc?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">‘Possible, But Not Probable': Steve Jobs' Witty Transportation Answer In 1973 Resume Earns Him Online Accolades — Bill Gates $15k Salary No Less Impressive In The Same Era</a></li>
</ul>
Image made via photos on Flickr and Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

$BTC

Tesla RoboCops? Chamath Palihapitiya On Joe Rogan's Podcast Envisions AI-Powered Law Enforcement

Reported Earlier, DDC Enterprise Announced The Launch Of Yai's Thai's New Series Of BBQ And Hot Sauces, Now Available At Sprouts Farmers Market

Oportun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>), a mission-driven financial services company, today announced that it has signed a definitive agreement to sell its credit card portfolio to Continental Finance. This transaction reflects a key milestone towards Oportun's initiative to enhance profitability in 2024 and beyond by simplifying the business and driving performance in its three core products: unsecured personal loans, secured personal loans, and its award-winning Set &amp; Save&#x2122; savings product.
The closing date is now anticipated to be on or around November 10, 2024, rather than by the end of the third quarter as indicated on the August 8th second quarter earnings call. Due to the revised closing date, the sale is expected to be accretive by approximately $2 million to Adjusted EBITDA in 2024 as compared to the $4 million previously indicated. Oportun continues to expect that the transaction will result in Adjusted EBITDA favorability of approximately $11 million in 2025.

Asset Sales

OPRT

Reported Earlier, Oportun Eyes $11M EBITDA Boost From Credit Card Portfolio Sale  to Continental Finance In 2025

MERC

Reported Earlier, Mercer International Announced That Its Peace River Mill Has Taken Downtime To Complete Necessary Repairs To The Mill's Digester After Experiencing A Mechanical Failure

Dividends

Reported Earlier, McDonald's Board Of Directors Raised A Quarterly Cash Dividend To $1.77, An Increase Of 6% Over The Previous Quarterly Dividend

CHCO

Reported Earlier, City Holding Company Raised A Dividend Per Share To 79 Cents From The 71.5 Cents, Payable On October 31, 2024 To Shareholders Of Record As Of October 15, 2024

FG Acquisition Corp. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FGAA#TSX">FGAA</a>)&nbsp;(TSX:<a class="ticker" href="https://www.benzinga.com/stock/FGAA#TSX">FGAA</a>) ("FGAC" or the "Corporation"), a special purpose acquisition company, is pleased to announce the successful completion of the previously announced acquisition (the "MDI Acquisition") of Strong/MDI Screen Systems, Inc. ("MDI") by FGAC, pursuant to an acquisition agreement (the "Acquisition Agreement") dated May 3, 2024 between FGAC, Strong Global Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGE#NYSE">SGE</a>) ("Strong Global"), MDI, FGAC Investors LLC (the "FG Sponsor") and CG Investments VII Inc (the "CG Sponsor" and together with FGAC Investors LLC, the "Sponsors"). The MDI Acquisition, together with the launch of FGAC's new investment platform, constitute FGAC's qualifying acquisition.
The Corporation is also pleased to announce it has completed an offering of 433,559 common shares (the "Common Shares") at a price of $10.00 per Common Share, for gross proceeds of approximately $4.3 million on a private placement basis (the "Private Placement").&nbsp; The net proceeds from the Private Placement will be used to satisfy a portion of the purchase price in respect of the MDI Acquisition, to fund the Company's growth initiatives, for working capital and for general corporate purposes.

Offerings

TSX:FGAA

Reported Earlier, FG Acquisition Completes $4.3M Private Placement Following Strong/MDI Acquisition

Reported Earlier, Walker & Dunlop Announced That It Has Financed $137.29M For Luka On The Common, A 398-unit, 30-story Trophy Asset Located In The Heart Of Downtown Boston

BIOA

Reported Earlier, BioAge Labs Announced The Pricing Of Its Upsized Initial Public Offering Of 11m Shares Of Its Common Stock At A Public Offering Price Of $18.00 Per Share

Guardian Pharmacy Services, Inc. ("Guardian") today announced the pricing of its upsized initial public offering of 8,000,000 shares of Class A common stock at a public offering price of $14.00 per share. In addition, Guardian has granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of Class A common stock at the public offering price, less the underwriting discount.
The shares are expected to begin trading on the New York Stock Exchange ("NYSE") on September 26, 2024, under the symbol "GRDN." The offering is expected to close on September 27, 2024, subject to customary closing conditions.

IPOs

GRDN

Reported Earlier, Guardian Pharmacy Services Raised $112M Via Initial Stock Offering Of 8M Shares At $14/Share, To Begin Trading Today

LUCY

Reported Earlier, Innovative Eyewear Announced That Its Board Of Directors Has Approved The Adoption Of A Limited Duration Stockholder Rights Plan And Declared A Dividend Distribution Of One Right For Each Outstanding Share Of Common Stock

LINC

Reported Earlier,  Lincoln Educational Services Announced The Introduction Of Air Conditioning, Refrigeration And Heating Systems Technology And Electrical And Electronic Systems Technology Career Training Programs At Its Moorestown Campus

Reported Earlier, KKR And The Skip Essential Infrastructure Fund Announced The Signing Of Definitive Agreements Under Which A Consortium Of The Companies Will Acquire A 74.25% Stake In Queensland Airports Limited At An Undisclosed Amount

Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today the pricing of its previously announced underwritten public offering of 23,125,001 of its ordinary shares at a price to the public of $8.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 1,875,023 ordinary shares at an offering price of $7.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant. &nbsp;
Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. All of the securities in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 of its ordinary shares on the same terms and conditions. The offering is expected to close on or about September 27, 2024, subject to customary closing conditions. &nbsp;

Reported Earlier, Wave Life Sciences Raised $200M Via Secondary Stock Offering Of 23.1M Shares At $8/Share

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Wednesday.
U.S. stocks settled mostly lower on Wednesday, with the Dow Jones index falling around 300 points during the session.
Shares of Stitch Fix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) dipped more than 39% on Wednesday after the company reported worse-than-expected fourth-quarter EPS results.
On the economic data front, U.S. building permits increased by 4.6% to an annual rate of 1.470 million in August. Sales of new single-family houses in the U.S. fell by 4.7% from the prior month to an annualized rate of 716,000 in August of 2024, compared to a revised 10.3% gain in the prior month.
Most sectors on the S&amp;P 500 closed on a negative note, with energy, health care, and financials stocks recording the biggest losses on Wednesday. However, information technology and utilities stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 293 points to 41,914.75 on Wednesday. The S&amp;P 500 fell 0.19% to 5,722.26, while the Nasdaq Composite gained 0.04% at 18,082.21 during Wednesday's session.
Investors are awaiting earnings results from Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>), Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>), and Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 67, the index remained in the &#8220;Greed&#8221; zone on Wednesday, versus a prior reading of 66.5.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41024505/top-5-industrials-stocks-that-may-collapse-in-q3">Top 5 Industrials Stocks That May Collapse In Q3</a></li>
</ul>

Pre-Market Outlook

COST

SFIX

Dow Tumbles Nearly 300 Points: Investor Optimism Improves Slightly, But Fear Index Remains In 'Greed' Zone

Reported Earlier, Darling Ingredients Announced That Its 50/50 Joint Venture Diamond Green Diesel Will Provide The First Regular Supply Of Sustainable Aviation Fuel To Florida Through An Agreement Between World Fuel And DHL Express

MDXH

Reported Earlier, MDxHealth Priced A Public Offering Of 20M Ordinary Shares Without Nominal Value At A Price To The Public Of $2.00 Per Share For Total Gross Proceeds Of $40.0M Before Deducting Commissions And Estimated Offering Expenses

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the New Drug Application (NDA) for picankibart injection, a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody, has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of moderate to severe plaque psoriasis. Picankibart is the first IL-23p19 antibody drug to show over 80% of subjects achieving PASI 90 after 16 weeks of treatment in a registrational Phase 3 clinical trial. It also offers the longest maintenance dosing interval (once every 12 weeks) among the same class of biologics. Picankibart is expected to deliver comprehensive benefits, including skin lesion clearance, improved medication convenience and enhanced quality of life for Chinese patients with moderate to severe plaque psoriasis.
This NDA acceptance is based on positive results from the Phase 3 registrational clinical study CLEAR-1 (NCT05645627) in Chinese patients with moderate to severe plaque psoriasis. The study successfully met its primary and all key secondary endpoints in May 2024, showing significantly higher rates of skin lesion clearance (PASI 90, PASI 75, PASI 100, sPGA 0/1, and sPGA 0) and quality of life improvement (DLQI 0/1) in the picankibart group compared to placebo. Picankibart showed a favorable safety profile, with no new safety signals. Detailed data from the CLEAR-1 study will be presented at future academic conferences and published in academic journals.

Government

Regulations

IVBIY

Innovent's Psoriasis Drug Picankibart Shows Results In Phase 3 Study, China Moves Forward With NDA

TOHO

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

TOHO

News

Latest news for TOHO (OTC:THOOF) Stock